- Home
- KFFB vs CGTX Comparison
KFFB vs CGTX Comparison
Compare KFFB & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFFB
- CGTX
- Stock Information
- Founded
- KFFB 2005
- CGTX 2007
- Country
- KFFB United States
- CGTX United States
- Employees
- KFFB N/A
- CGTX N/A
- Industry
- KFFB Savings Institutions
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KFFB Finance
- CGTX Health Care
- Exchange
- KFFB Nasdaq
- CGTX Nasdaq
- Market Cap
- KFFB 21.0M
- CGTX 20.5M
- IPO Year
- KFFB 2005
- CGTX 2021
- Fundamental
- Price
- KFFB $2.90
- CGTX $0.30
- Analyst Decision
- KFFB
- CGTX Strong Buy
- Analyst Count
- KFFB 0
- CGTX 5
- Target Price
- KFFB N/A
- CGTX $5.63
- AVG Volume (30 Days)
- KFFB 6.8K
- CGTX 1.9M
- Earning Date
- KFFB 05-12-2025
- CGTX 08-07-2025
- Dividend Yield
- KFFB N/A
- CGTX N/A
- EPS Growth
- KFFB N/A
- CGTX N/A
- EPS
- KFFB N/A
- CGTX N/A
- Revenue
- KFFB $8,308,000.00
- CGTX N/A
- Revenue This Year
- KFFB N/A
- CGTX N/A
- Revenue Next Year
- KFFB N/A
- CGTX N/A
- P/E Ratio
- KFFB N/A
- CGTX N/A
- Revenue Growth
- KFFB 13.79
- CGTX N/A
- 52 Week Low
- KFFB $1.96
- CGTX $0.22
- 52 Week High
- KFFB $3.62
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- KFFB 56.78
- CGTX 48.87
- Support Level
- KFFB $2.61
- CGTX $0.25
- Resistance Level
- KFFB $2.78
- CGTX $0.33
- Average True Range (ATR)
- KFFB 0.16
- CGTX 0.03
- MACD
- KFFB 0.01
- CGTX 0.00
- Stochastic Oscillator
- KFFB 50.67
- CGTX 58.69
About KFFB Kentucky First Federal Bancorp
Kentucky First Federal Bancorp is a holding company. The company through its subsidiaries is engaged mainly in the business of accepting deposits from the general public and using such funds to originate loans secured by first mortgages on owner-occupied, residential real estate and other loans secured by real estate. Its primary products and services include Residential mortgage loans, Multi-family loans, Construction loans and types of deposits, etc. The company mainly operates in Perry, Franklin, Boyle and Garrard and surrounding counties in Kentucky, US.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.